Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, June 01 2022 - 21:00
Cambrex Acquires Leading EU Stability Storage Company Q1 Scientific
EAST RUTHERFORD, NJ, June 1, 2022, /PRNewswire-AsiaNet/ --

Cambrex, a leading global contract development and manufacturing organization 
(CDMO) providing drug substance, drug product, and analytical services across 
the entire drug lifecycle, today announced the acquisition of Q1 Scientific – a 
leading provider of environmentally-controlled cGMP stability storage services 
for the pharmaceutical, medical device and life science industries, 
strategically located in Waterford, Ireland.

"Stability storage and testing is a critical component of drug development and 
commercialization of new therapies. Q1 Scientific brings world-class 
capabilities to our ever-expanding portfolio of outsourced pharmaceutical 
services." said Tom Loewald, CEO, Cambrex. "This acquisition is a natural 
extension of our current offerings that will broaden and increase our expertise 
in this critical area, as well as our footprint in the European market."

Q1 Scientific's state-of-the-art cGMP facility is ICH validated to meet the 
specific storage requirements of any pharmaceutical project, with options from 
-80 C storage up to +50 C, with a full range of humidity control. The 20,000 
sq. ft. Waterford facility boasts nearly 40 walk-in stability storage chambers, 
reach-in freezers and stability units, and ultra-low temperature freezers for 
biologic therapies. The company also provides sample management and transport 

"We're pleased to join Cambrex as we continue to provide leading stability 
storage services to our current customers," said Stephen Delaney, CEO, Q1 
Scientific. "With Cambrex's scientific expertise and scale, we'll be able to 
accelerate our growth and offer an integrated suite of analytical services, 
providing a full range of market-leading solutions for our customers."

Cambrex offers a variety of storage and testing capabilities with walk-in and 
reach-in chambers that meet the ICH Q1A requirements. The acquisition will 
expand Cambrex's capabilities into the European market.

As pharmaceutical and biopharmaceutical companies continue to seek outsourcing 
options for non-core capabilities to reduce their footprint, Q1 Scientific's 
stability storage services, combined with Cambrex's industry-leading analytical 
services portfolio, provide specialized capabilities of high value to the 

About Cambrex
Cambrex is a leading global contract development and manufacturing organization 
(CDMO) that provides drug substance, drug product, and analytical services 
across the entire drug lifecycle. With over 40 years of experience and a 
growing team of over 2,200 experts servicing global clients from North America 
and Europe, Cambrex is a trusted partner in branded and generic markets for API 
and finished dosage form development and manufacturing.

Cambrex offers a range of specialized drug substance technologies and 
capabilities, including biocatalysis, continuous flow, controlled substances, 
solid-state science, material characterization, and highly potent APIs. In 
addition, Cambrex can support conventional dosage forms, including oral solids, 
semi-solids, and liquids, and has the expertise to manufacture specialty dosage 
forms such as modified-release, fixed-dose combination, pediatric, bi-layer 
tablets, stick packs, topicals, controlled substances, sterile, and non-sterile 

About Q1 Scientific
Q1 Scientific was founded in Waterford, Ireland in 2013 by Louise Grubb, and 
offers environmentally controlled stability storage services to the 
pharmaceutical, medical device and life sciences industries at their 20,000 sq 
ft. cGMP facility. As the first company in the sector to establish in Ireland, 
Q1 Scientific is revolutionizing the way pharmaceutical companies store their 
products, helping to improve the speed it takes for new drugs to reach the 
marketplace along with saving companies the expense of building and monitoring 
their own storage chambers.

For more information, visit or

Jennifer Therrien